Author:
Bakker Wilfried A.M.,Thomassen Yvonne E.,van der Pol Leo A.
Reference13 articles.
1. Aylward, R.B., Sutter, R.W., Cochi, S.L., Thompson, K.M., Jafari, H., and Heymann, D. (2006) Risk management in a polio-free world. Risk Analysis 26(6), 1441–1448.
2. FDA. (2004) Guidance for Industry : PAT – A framework for innovative pharmaceutical development, manufacturing, and quality assurance.
http://www.fda.gov/cder/guidance/index.htm
3. Jolliffe, I.T. (2002) Principal Component Analysis, Springer Series in Statistics, 2nd ed. Springer.
4. Kirdar, A.O., Conner, J.S., Baclaski, J., and Rathore, A.S. (2007) Application of multivariate analysis toward biotech processes: case study of a cell-culture unit operation. Biotechnol. Prog. 23(1), 61–67.
5. Montagnon, B.J., Fanget, B., and Vincent-Falquet, J.C. (1984) Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier. Rev. Infect. Dis. 6(S2), S341–S344.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献